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Abstract The REtsAF cell line expresses a temperature-
sensitive mutant of the SV40 large tumor antigen. At restrictive
temperature (39.5‡C), the cells undergo p53-mediated apoptosis,
which can be inhibited by Bcl-2. Here, we show that Z-VAD-
fmk, a caspase inhibitor, can suppress the Bcl-2-dependent cell
survival at 39.5‡C. This result suggests that a caspase-like
activity can act as an inhibitor of apoptosis in this model,
downstream of Bcl-2. Our results also suggest that this activity
may be up-regulated by Bcl-2 and may be responsible for
cleavage of the tumor suppressor Rb protein.
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1. Introduction
Apoptosis is a process whereby cells activate an intrinsic
death program leading to the elimination of unwanted or
potentially dangerous cells. The existence of such a program
was ascertained through genetic studies in the nematode Cae-
norhabditis elegans that identi¢ed genes involved in the cell
death program and its control [1]. The ced-3 and ced-4 genes
are required to the execution of cell death whereas the ced-9
gene promotes cell survival by inhibiting the death activities of
ced-3 and ced-4 [2].
CED-3 protein turned out to be a member of a family of
cysteine aspartases, known as caspases [3]. These proteases are
supposed to form the core of the cell death machinery. All the
caspases appear to be synthesized as proenzymes and are pro-
teolytically activated. The upstream ‘activating caspases’ are
able to autoactivate in response to death signals and can
activate the downstream ‘execution caspases’ which would in
turn mediate apoptosis by destroying cellular proteins [4].
CED-4 protein interacts directly with CED-3 and promotes
its processing and activation [5]. The apoptosis protease-acti-
vating factor 1 (Apaf-1) would be a mammalian equivalent of
CED-4 [6]. CED-9 protein is homologous to the mammalian
Bcl-2 family which contains members that inhibit apoptosis,
such as Bcl-2 or Bcl-xL [7]. It has been shown in both worm
and mammalian cells that the anti-apoptotic members of the
Bcl-2 family act upstream of the ‘execution caspases’, some-
how preventing their proteolytic processing into active killers
[2,8].
In order to better understand the mechanisms that govern
cell death versus cell survival, we used a rat embryo ¢broblast
cell line (REtsAF), conditionally immortalized with a temper-
ature-sensitive mutant (tsA58) of the simian virus 40 large
tumor antigen (LT). At permissive temperature (33‡C), LT
immortalizes these rodent cells via the inhibition of p53 and
Rb tumor suppressor proteins [9,10]. At restrictive tempera-
ture (39.5‡C), inactivation of LT leads to p53 activation and
apoptosis of the REtsAF cells [11]. It has previously been
shown that apoptosis of REtsAF cells is inhibited by Bcl-2
[12]. In an attempt to better understand the relationships be-
tween the anti-apoptotic Bcl-2 and caspases to regulate cell
death, we used caspase inhibitors (Z-VAD-fmk, Z-DEVD-fmk
and YVAD-cmk) on REtsAF cells conditionally expressing
Bcl-2. Here, we show that the Bcl-2-mediated survival of RE-
tsAF cells at 39.5‡C involves at least one Z-VAD-fmk-sensi-
tive protease. Furthermore, the accumulation of the truncated
Rb protein in bcl-2-expressing cells raises the possibility that
this protease is responsible for Rb cleavage.
2. Materials and methods
2.1. Cell lines and cell culture
The isolation of the REtsAF cell line and the development of the
P1-Bcl-2 cell line have been described previously [12,13]. The cells
were propagated at 33‡C in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with penicillin (100 Wg/ml), streptomycin
(100 U/ml) and 10% fetal calf serum (Gibco). The P1-Bcl-2 cells
were routinely maintained in the presence of tetracycline (2 Wg/ml)
to inhibit the expression of exogenous bcl-2. The P1-Bcl-2 cells were
propagated for 10 days without tetracycline in the culture medium, in
order to allow accumulation of the Bcl-2 protein.
2.2. Caspase inhibitor treatments
The cells were seeded in 60 mm dishes and shifted to 39.5‡C, or
incubated with staurosporine (0.5 WM) at 33‡C, when they reached
50% con£uence. Z-VAD-fmk (100 WM), Z-DEVD-fmk (100 WM) and
YVAD-cmk (300 WM) were added just before the shift of temperature
or staurosporine addition. The percentage of surviving cells was eval-
uated by determining the proportion of attached cells (estimated by
the crystal violet method), expressed as a percentage of the zero time
population. Pictures of the cells were taken after 48 h at 39.5‡C under
a Nikon TMS microscope equipped with a Nikon F601 camera.
2.3. Western blot analysis
The cells were seeded in 100 mm dishes and shifted to 39.5‡C when
they reached 50% con£uence. At di¡erent times, cells were rinsed in
cold PBS, collected with a scraper and frozen at 380‡C. Proteins (80
Wg) were separated by SDS-page (in 7.5% acrylamide 0.1% bisacryla-
mide) and transferred to PVDF membranes (Boehringer Mannheim)
according to Towbin et al. [14]. Blots were exposed to the mouse anti-
Rb antibody (G3-245, Pharmingen) overnight at 4‡C, rinsed in PBS/
Tween 20 at 0.5% and exposed for 1 h, at room temperature, to
horseradish peroxidase-conjugated anti-mouse immunoglobulin serum
(Biosystem). The immunoreactivity was revealed using the Amersham
ECL kit.
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3. Results
3.1. Bcl-2-dependent cell survival at 39.5‡C is suppressed by
Z-VAD-fmk, a caspase inhibitor
We had previously developed the P1-Bcl-2 cell line which is
derived from REtsAF cells and expresses the human bcl-2
gene, under control of tetracycline [12,15]. When tetracycline
(Tet) is added to the culture medium, expression of exogenous
bcl-2 is repressed and the cells behave like untransfected RE-
tsAF cells. After tetracycline withdrawal, bcl-2 is overex-
pressed and protects the cells from apoptosis at 39.5‡C [12].
Bcl-2, like other members of its family, can inhibit apoptosis
by preventing activation of caspases (for review see [16]). In
order to further examine the relationships between Bcl-2 and
caspases, we treated the P1-Bcl-2 cells with caspase inhibitors.
We ¢rst used Z-VAD-fmk, a broad-spectrum caspase inhibi-
tor which inhibits apoptosis in many models [17,18].
Comparison between P1-Bcl-2 cells with Tet and without
Tet at 39.5‡C (Fig. 1) con¢rms that the cells are protected
from apoptosis when exogenous bcl-2 is expressed (3Tet).
Unexpectedly, the Z-VAD-fmk treatment of P1-Bcl-2 cells
with or without Tet does not protect against apoptosis, but
accelerates cell death (Fig. 1). Fig. 1 even shows that addition
of Z-VAD-fmk totally abolishes the cell survival brought
about by the expression of exogenous bcl-2. This result is very surprising because Z-VAD-fmk is an inhibitor of casp-
ases, which are killer proteases. Thus, we tried to determine if
Z-VAD-fmk was toxic for the cells.
Incubation of P1-Bcl-2 cells with or without Tet with Z-
VAD-fmk (100 WM), for 72 h at 33‡C, does not change the
viability of the cells (data not shown). Moreover, we incu-
bated a cell line obtained from REtsAF, termed Rev-tsAF,
with Z-VAD-fmk at 39.5‡C. In this cell line, LT lost its tem-
perature sensitivity and the cells were immortalized at 33‡C
and 39.5‡C. We observed that Z-VAD-fmk did not kill the
Rev-P1 cells at 39.5‡C (data not shown). Taken together,
these results show that Z-VAD-fmk is not toxic for the cells.
Next, we incubated the P1-Bcl-2 cells with di¡erent concen-
trations of Z-VAD-fmk for 24 h at 39.5‡C. Fig. 2 shows that
survival of cells with or without Tet decreases in a dose-de-
pendent manner, suggesting that the action of Z-VAD-fmk is
speci¢c.
Taken together, these results raise the possibility that a Z-
VAD-fmk-sensitive protease activity negatively regulates
apoptosis in this system. Since Z-VAD-fmk totally abolishes
the e¡ect of bcl-2 overexpression, we also postulated that this
protease activity would occur downstream of Bcl-2 to inhibit
apoptosis. The fact that cell death is also accelerated by Z-
VAD-fmk when expression of the exogenous bcl-2 is repressed
(+Tet) (Figs. 1 and 2) may be due to the inhibition of the
endogenous Bcl-2-dependent cell survival.
3.2. The pro-apoptotic e¡ect of Z-VAD-fmk at 39.5‡C is
related to its peptide sequence
To further examine the hypothesis of a protease as a medi-
ator of Bcl-2-dependent cell survival, we veri¢ed the speci¢city
of Z-VAD-fmk action, compared to other caspase inhibitors.
A synthetic caspase inhibitor contains a peptide recognition
element, corresponding to those found in endogenous sub-
strates, as well as a chemical function such as aldehyde
(CHO) for the reversible inhibitors, or chloromethylketone
(cmk) and £uoromethylketone (fmk) for the irreversible inhib-
itors [19]. To perform this analysis, we used the Z-DEVD-fmk
Fig. 1. Bcl-2-dependent survival is suppressed by Z-VAD-fmk, a
caspase inhibitor. P1-Bcl-2 cells plus tetracycline and P1-Bcl-2 cells
without tetracycline were treated with Z-VAD 100 WM or not
treated just before the shift of temperature. Z-VAD-fmk accelerates
death of cells with and without Tet, and abolishes the survival e¡ect
of bcl-2 overexpression in cells without Tet. Pictures of the cells
were taken at 48 h of treatment.
Fig. 2. In£uence of Z-VAD-fmk concentration on cell survival at
39.5‡C. P1-Bcl-2 cells with or without Tet were incubated for 24 h
with di¡erent concentrations of Z-VAD-fmk: 0^100 WM. Death of
the cells with or without Tet increases in a dose-dependent manner
showing that the action of Z-VAD-fmk is speci¢c.
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and the YVAD-cmk inhibitors, which are both irreversible
but present distinct inhibitory spectra. Z-DEVD-fmk prefer-
entially inhibits execution caspases [19], whereas YVAD-cmk
inhibits the caspase-1 family, which is involved in interleukin-
1L maturation [3].
Fig. 3 indicates that Z-DEVD-fmk and Z-VAD-fmk have
opposite e¡ects, showing that the action of Z-VAD-fmk is
speci¢c and related to its peptide sequence. This result also
suggests that Z-VAD-fmk acts on an anti-apoptotic protease
which does not belong to the execution caspase family.
3.3. Action of Z-VAD-fmk is dependent on the cell death
inducer
A pro-apoptotic e¡ect for Z-VAD-fmk contradicts data of
the literature, in which Z-VAD-fmk inhibits activation of ex-
ecution caspases and apoptosis. In order to determine the
origin of this di¡erence, we induced apoptosis in P1-Bcl-2 cells
at 33‡C with staurosporine. It has been shown that stauro-
sporine-induced apoptosis is inhibited by Z-VAD-fmk [17].
Fig. 4 shows that the cell death induced by staurosporine in
P1-Bcl-2 cells at 33‡C is inhibited by both Bcl-2 and Z-VAD-
fmk. As expected, Bcl-2 and Z-VAD-fmk apparently have
overlapping activities because addition of Z-VAD-fmk on
P1-Bcl-2, overexpressing Bcl-2 (3Tet), does not increase the
cell survival. These results are in agreement with the roles of
Bcl-2 and Z-VAD-fmk reported in the literature and show
that the pro-apoptotic action of Z-VAD-fmk is probably re-
lated to the death signaling pathway activated by p53 at
39.5‡C.
3.4. Evidence for cleavage of a cellular protein up-regulated by
Bcl-2 and inhibited by Z-VAD-fmk
The hypothesis of a protease mediating cell survival down-
stream of Bcl-2 suggests that Bcl-2 could activate this protease
and enhance the production of some truncated cellular sub-
strate that favors cell survival. We studied the status of pro-
teins that regulate apoptosis, such as Bax, Bcl-2 or Bcl-xL, and
proteins that regulate cell cycle progression, such as p53, Waf-
1 and Rb, in REtsAF and P1-Bcl-2 cells. Among these pro-
teins, we observed that Rb can be a target of such a protease.
A Western blot analysis of the tumor suppressor Rb pro-
tein, during kinetics at 39.5‡C in P1-Bcl-2 cells with or with-
out Tet, reveals several forms of Rb in cellular extracts (Fig.
5). These forms of Rb are the hypo- (p105)/hyper- (p110)
phosphorylated forms, the truncated p100 form described by
Chen et al. [20] and the truncated p68 form, identi¢ed by An
and Dou [21], which is truncated in the N-terminus of Rb.
Unlike p100, the p68 truncated form of Rb is present in P1-
Bcl-2 cells (3Tet) overexpressing bcl-2 but undetectable in P1-
Bcl-2 cells with Tet. In order to verify that tetracycline did not
suppress p68 production on its own, we added tetracycline to
Fig. 3. E¡ects of di¡erent caspase inhibitors on cell survival at
39.5‡C. P1-Bcl-2 cells with or without Tet were incubated for 48 h
at 39.5‡C with the caspase inhibitors Z-VAD-fmk, Z-DEVD-fmk or
YVAD-cmk, or were not treated. Z-VAD-fmk increases cell death
of cells with and without Tet whereas the Z-DEVD-fmk inhibits cell
death. YVAD-cmk has no signi¢cant e¡ect on cell survival. The dif-
ferent activities of Z-VAD-fmk and Z-DEVD-fmk demonstrate that
the pro-apoptotic e¡ect of Z-VAD-fmk is related to its peptide se-
quence.
Fig. 4. In£uence of Z-VAD-fmk on apoptosis induced by stauro-
sporine. P1-Bcl-2 cells with or without Tet were incubated for 48 h
with the caspase inhibitor Z-VAD-fmk, or were not treated, just be-
fore the addition of staurosporine (0.5 WM). The Z-VAD-fmk inhib-
itor increases cell survival of cells with Tet but has no e¡ect on cells
without Tet, in contrast to apoptosis at 39.5‡C.
Fig. 5. Bcl-2 activates the cleavage of the Rb protein. P1-Bcl-2 cells
with Tet and P1-Bcl-2 cells without Tet were incubated at 39.5‡C
for di¡erent times. Treatment with Z-VAD-fmk was done just be-
fore the shift at 39.5‡C, where indicated (Z). This Western blot
analysis reveals that the production of the truncated p68 form of
the Rb protein increases with bcl-2 expression and is inhibited by
Z-VAD-fmk.
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another tsA58/LT-immortalized cell line (REtsA15) which
survives at 39.5‡C and naturally produces p68 at 33‡C and
39.5‡C. No di¡erence was obtained in p68 production be-
tween REtsA15 cells without or with Tet (data not shown).
Since p68 production is inhibited by Z-VAD-fmk, these re-
sults show that Bcl-2 is actually able to activate, directly or
indirectly, a Z-VAD-fmk-sensitive protease which is involved
in Rb cleavage and p68 production. The fact that p68 is de-
tected at 33‡C, speci¢cally in P1-Bcl-2 cells without Tet, re-
inforces the idea that Bcl-2 itself regulates the corresponding
protease activity, independently of p53 activation at 39.5‡C.
Furthermore, the accumulation of p68 in bcl-2-expressing cells
raises the possibility that the Bcl-2-regulated anti-apoptotic
protease is responsible for cleavage of Rb.
4. Discussion
The data described above provide evidence of a new path-
way for Bcl-2 to inhibit cell death. We have shown that Z-
VAD-fmk, a caspase inhibitor, can speci¢cally abolish the
survival e¡ect brought about by the overexpression of bcl-2
in P1-Bcl-2 cells at 39.5‡C. Thus, it appears that a caspase-like
protein is required downstream of Bcl-2 to mediate its survival
e¡ect in this model. Moreover, our results suggest that this
protease activity may be up-regulated by Bcl-2 and may be
responsible for cleavage of the Rb protein.
The caspase inhibitor Z-VAD-fmk has an anti-apoptotic
activity in staurosporine-induced apoptosis and a pro-apop-
totic activity in p53-mediated apoptosis at 39.5‡C. Thus, we
postulate that p53- and staurosporine-induced apoptosis do
not involve the same pattern of caspases, and/or the same
roles for caspases in cell death. Data in the literature about
the relationships between p53-induced apoptosis and the role
of caspases are contradictory. Some studies report that p53-
dependent apoptosis involves activation of caspases [22]
whereas others show that it can occur independently of exe-
cution caspases [23]. The fact that a broad-spectrum caspase
inhibitor (Z-VAD-fmk) has the ability to kill the P1-Bcl-2 cells
at 39.5‡C suggests that a death signal, independent of casp-
ases, exists in this system. This signal could be antagonized by
Bcl-2 in a pathway requiring the putative protease.
Whether a protease favors cell death or cell survival de-
pends on its targets. In this way, p68 or another substrate
truncated by the same protease could mediate the Bcl-2-de-
pendent survival. This hypothesis is consistent with previous
reports which show that caspases can act as post-translational
modi¢ers, enhancing some protein activities such as interleu-
kin-1L [24] or the Rb protein [20]. Indeed, the truncated p100
form of Rb has been described as having an enhanced a⁄nity
and an increased inhibitory potential for E2F transcription
factors [20,25]. Since E2F-1 has the ability to induce apoptosis
on its own [26], or in cooperation with p53 [27], E2F-1 may be
involved in triggering apoptosis in our model, and p68 may
have particular properties to counteract these apoptotic ef-
fects.
Another key component of the possible new pathway for
Bcl-2 to inhibit apoptosis could be the cell growth and tumor
suppressor PML, which is a mediator of multiple apoptotic
signals. Indeed, PML death has recently been reported to be
accelerated by Z-VAD-fmk [28]. Unfortunately, no connec-
tions between PML and Bcl-2 have been established yet.
But the information that we have collected concerning the
properties and the regulation of the activity of such a protease
could facilitate its identi¢cation.
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